Education
About Us
Working with TipRanks
Follow Us
Collegium Pharmaceutical (COLL)
NASDAQ:COLL
COLL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$27.28 - $42.29
Previous CloseN/A
Volume233.62K
Average Volume (3M)427.29K
Market Cap
$946.14M
Enterprise Value$2.40B
Total Cash (Recent Filing)$70.56M
Total Debt (Recent Filing)$237.17M
Price to Earnings (P/E)16.3
Beta0.26
Next Earnings
May 08, 2025EPS Estimate
1.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.85
Shares Outstanding31,485,523
10 Day Avg. Volume552,350
30 Day Avg. Volume427,294
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)N/A
Price to Sales (P/S)1.50
Price to Cash Flow (P/CF)2.80
P/FCF Ratio2.80
Enterprise Value/Market Cap2.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.36
Enterprise Value/Ebitda8.47
Forecast
1Y Price Target
$43.00Price Target Upside43.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Collegium Pharmaceutical News
PremiumCompany Announcements
Collegium Pharmaceutical Appoints New Executive VP and General Counsel
PremiumCompany Announcements
Collegium Pharma’s Earnings Call Highlights Growth and Strategy
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCOLL reported a solid 4Q24 top-line of $181.9MM, vs. Street's $179.8MM, on the strength of Xtampza and Belbuca, due to Rx growth and improved GTNs.
UndervaluationThe stock price appears undervalued, with potential for significant appreciation as the market recognizes the durability of the company's pain portfolio.
Bears Say
Guidance LimitationsCollegium historically doesn’t give product-level guidance, but specified that recently-acquired JORNAY PM should exceed $135M, which is projected to be over 32% pro forma year-over-year growth.
Seasonality ImpactSeasonality factors typically lead to a revenue step-down in the first quarter, affecting the company's financial performance compared to the fourth quarter.
---
Ownership Overview
4.44% Insiders
37.98% Mutual Funds
0.90% Other Institutional Investors
24.03% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
COLL FAQ
What was Collegium Pharmaceutical’s price range in the past 12 months?
Collegium Pharmaceutical lowest stock price was $27.27 and its highest was $42.29 in the past 12 months.
What is Collegium Pharmaceutical’s market cap?
Collegium Pharmaceutical’s market cap is $946.14M.
When is Collegium Pharmaceutical’s upcoming earnings report date?
Collegium Pharmaceutical’s upcoming earnings report date is May 08, 2025 which is in 44 days.
How were Collegium Pharmaceutical’s earnings last quarter?
Collegium Pharmaceutical released its earnings results on Feb 27, 2025. The company reported $1.77 earnings per share for the quarter, beating the consensus estimate of $1.538 by $0.232.
Is Collegium Pharmaceutical overvalued?
According to Wall Street analysts Collegium Pharmaceutical’s price is currently Undervalued.
Does Collegium Pharmaceutical pay dividends?
Collegium Pharmaceutical does not currently pay dividends.
What is Collegium Pharmaceutical’s EPS estimate?
Collegium Pharmaceutical’s EPS estimate is 1.5.
How many shares outstanding does Collegium Pharmaceutical have?
Collegium Pharmaceutical has 31,485,523 shares outstanding.
What happened to Collegium Pharmaceutical’s price movement after its last earnings report?
Collegium Pharmaceutical reported an EPS of $1.77 in its last earnings report, beating expectations of $1.538. Following the earnings report the stock price went up 2.217%.
Which hedge fund is a major shareholder of Collegium Pharmaceutical?
Currently, no hedge funds are holding shares in COLL
---
Collegium Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.00 (43.09% Upside)
$43.00 (43.09% Upside)
Blogger Sentiment
Bullish
COLL Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 97.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.8%
Last 30 Days ▼ 8.8%
Last 30 Days ▼ 8.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.23%
12-Months-Change
Fundamentals
Return on Equity
32.62%
Trailing 12-Months
Asset Growth
45.51%
Trailing 12-Months
Company Description
Collegium Pharmaceutical
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta IR is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Stoughton, MA.
---
COLL Company Deck
---
COLL Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in Jornay PM and a strong financial position, supported by strategic acquisitions and expansions. Despite a decline in Nucynta revenue and increased operating expenses, the overall outlook remains positive due to strong performance in the pain portfolio and strategic initiatives.Read More>---
COLL Stock 12 Month Forecast
Average Price Target
$43.00
▲(43.09% Upside)
Technical Analysis
Best Analysts Covering COLL
1 Year
1 Year Success Rate
14/33 ratings generated profit
1 Year Average Return
+5.38%
reiterated a buy rating 25 days ago
Copying Serge Belanger's trades and holding each position for 1 Year would result in 42.42% of your transactions generating a profit, with an average return of +5.38% per trade.
---